Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia
Alzheimer’s disease (AD) is the primary type of dementia, followed by frontotemporal lobar degeneration (FTLD). They share some clinical characteristics, mainly at the early stages. So, the identification of early, specific, and minimally invasive biomarkers is required. In this study, some plasma b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/2/1226 |
| _version_ | 1797441511731757056 |
|---|---|
| author | Lourdes Álvarez-Sánchez Carmen Peña-Bautista Laura Ferré-González Angel Balaguer Miguel Baquero Bonaventura Casanova-Estruch Consuelo Cháfer-Pericás |
| author_facet | Lourdes Álvarez-Sánchez Carmen Peña-Bautista Laura Ferré-González Angel Balaguer Miguel Baquero Bonaventura Casanova-Estruch Consuelo Cháfer-Pericás |
| author_sort | Lourdes Álvarez-Sánchez |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the primary type of dementia, followed by frontotemporal lobar degeneration (FTLD). They share some clinical characteristics, mainly at the early stages. So, the identification of early, specific, and minimally invasive biomarkers is required. In this study, some plasma biomarkers (Amyloid β42, p-Tau181, t-Tau, neurofilament light (NfL), TAR DNA-binding protein 43 (TDP-43)) were determined by single molecule array technology (SIMOA<sup>®</sup>) in control subjects (<i>n</i> = 22), mild cognitive impairment due to AD (MCI-AD, <i>n</i> = 33), mild dementia due to AD (<i>n</i> = 12), and FTLD (<i>n</i> = 11) patients. The correlations between plasma and cerebrospinal fluid (CSF) levels and the accuracy of plasma biomarkers for AD early diagnosis and discriminating from FTLD were analyzed. As result, plasma p-Tau181 and NfL levels correlated with the corresponding CSF levels. Additionally, plasma p-Tau181 showed good accuracy for distinguishing between the controls and AD, as well as discriminating between AD and FTLD. Moreover, plasma NfL could discriminate dementia-AD vs. controls, FTLD vs. controls, and MCI-AD vs. dementia-AD. Therefore, the determination of these biomarkers in plasma is potentially helpful in AD spectrum diagnosis, but also discriminating from FTLD. In addition, the accessibility of these potential early and specific biomarkers may be useful for AD screening protocols in the future. |
| first_indexed | 2024-03-09T12:24:07Z |
| format | Article |
| id | doaj.art-cac875bad9764e9d97ccf76aaa801fa4 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T12:24:07Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-cac875bad9764e9d97ccf76aaa801fa42023-11-30T22:37:15ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-01-01242122610.3390/ijms24021226Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal DementiaLourdes Álvarez-Sánchez0Carmen Peña-Bautista1Laura Ferré-González2Angel Balaguer3Miguel Baquero4Bonaventura Casanova-Estruch5Consuelo Cháfer-Pericás6Alzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, SpainAlzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, SpainAlzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, SpainFaculty of Mathematical Sciences, University of Valencia, 46100 Burjassot-Valencia, SpainAlzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, SpainDivision of Neurology, University and Polytechnic Hospital La Fe, 46026 Valencia, SpainAlzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, SpainAlzheimer’s disease (AD) is the primary type of dementia, followed by frontotemporal lobar degeneration (FTLD). They share some clinical characteristics, mainly at the early stages. So, the identification of early, specific, and minimally invasive biomarkers is required. In this study, some plasma biomarkers (Amyloid β42, p-Tau181, t-Tau, neurofilament light (NfL), TAR DNA-binding protein 43 (TDP-43)) were determined by single molecule array technology (SIMOA<sup>®</sup>) in control subjects (<i>n</i> = 22), mild cognitive impairment due to AD (MCI-AD, <i>n</i> = 33), mild dementia due to AD (<i>n</i> = 12), and FTLD (<i>n</i> = 11) patients. The correlations between plasma and cerebrospinal fluid (CSF) levels and the accuracy of plasma biomarkers for AD early diagnosis and discriminating from FTLD were analyzed. As result, plasma p-Tau181 and NfL levels correlated with the corresponding CSF levels. Additionally, plasma p-Tau181 showed good accuracy for distinguishing between the controls and AD, as well as discriminating between AD and FTLD. Moreover, plasma NfL could discriminate dementia-AD vs. controls, FTLD vs. controls, and MCI-AD vs. dementia-AD. Therefore, the determination of these biomarkers in plasma is potentially helpful in AD spectrum diagnosis, but also discriminating from FTLD. In addition, the accessibility of these potential early and specific biomarkers may be useful for AD screening protocols in the future.https://www.mdpi.com/1422-0067/24/2/1226Alzheimer’s diseasefrontotemporal dementiaplasmabiomarkerSIMOAdiagnosis |
| spellingShingle | Lourdes Álvarez-Sánchez Carmen Peña-Bautista Laura Ferré-González Angel Balaguer Miguel Baquero Bonaventura Casanova-Estruch Consuelo Cháfer-Pericás Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia International Journal of Molecular Sciences Alzheimer’s disease frontotemporal dementia plasma biomarker SIMOA diagnosis |
| title | Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia |
| title_full | Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia |
| title_fullStr | Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia |
| title_full_unstemmed | Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia |
| title_short | Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia |
| title_sort | assessment of plasma and cerebrospinal fluid biomarkers in different stages of alzheimer s disease and frontotemporal dementia |
| topic | Alzheimer’s disease frontotemporal dementia plasma biomarker SIMOA diagnosis |
| url | https://www.mdpi.com/1422-0067/24/2/1226 |
| work_keys_str_mv | AT lourdesalvarezsanchez assessmentofplasmaandcerebrospinalfluidbiomarkersindifferentstagesofalzheimersdiseaseandfrontotemporaldementia AT carmenpenabautista assessmentofplasmaandcerebrospinalfluidbiomarkersindifferentstagesofalzheimersdiseaseandfrontotemporaldementia AT lauraferregonzalez assessmentofplasmaandcerebrospinalfluidbiomarkersindifferentstagesofalzheimersdiseaseandfrontotemporaldementia AT angelbalaguer assessmentofplasmaandcerebrospinalfluidbiomarkersindifferentstagesofalzheimersdiseaseandfrontotemporaldementia AT miguelbaquero assessmentofplasmaandcerebrospinalfluidbiomarkersindifferentstagesofalzheimersdiseaseandfrontotemporaldementia AT bonaventuracasanovaestruch assessmentofplasmaandcerebrospinalfluidbiomarkersindifferentstagesofalzheimersdiseaseandfrontotemporaldementia AT consuelochaferpericas assessmentofplasmaandcerebrospinalfluidbiomarkersindifferentstagesofalzheimersdiseaseandfrontotemporaldementia |